Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Theme
Exploring the novel research and innovations in Cell and Gene therapy
- Cell Biology and Gene Therapy 2017

About

 Allied Academic Publication is an amalgamation of several esteemed academic and scientific associations known for promoting scientific temperament. Established in the year 1997, Andrew John Publishing Group is a specialized Medical publisher that operates in collaboration with the association and societies.  This publishing house has been built on the base of esteemed academic and research institutions including The College of Audiologists and Speech-Language Pathologists of Ontario(CASLPO), The Association of Public-Safety Communications Officials of Canada (APCO), The Canadian Vascular Access Association (CVAA), The Canadian Society of Internal Medicine (CSIM), The Canadian Hard of Hearing Association (CHHA), Sonography Canada, Canadian Association of Pathologists (CAP-ACP) and The Canadian Association of Neurophysiologic Monitoring (CANM).

Welcome Message

Allied Academics welcome all the participants to the “International Congress on Cell Biology and Gene Therapy "held during October 25-27, 2017 in Toronto, Canada. Cell Therapy Conferences will provide a perfect platform to all the Doctors, Researchers Business Delegates, and Scientists to approach and deliver all the attendees about the latest scientific advancements on the respective sphere.

Gene Therapy Conferences strategic astuteness is to be an event for bringing together Scientists, Physicians, International mix of leading Universities, Cell Gene Therapy Institutions to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.

This two-day Gene Therapy Event will address key issues concerning cell and gene therapy in the broader context of the cellular and genetic disorder. Organized around daily themes, the Conference focuses on moving from present knowledge to future solutions

Target Audience

 Cell and Gene Therapy Students, Scientists

 Cell and Gene Therapy Researchers

 Cell and Gene Therapy Faculty

 Cell and Gene Therapy Associations and Societies

 Cell and Gene Therapy physicians

 Cell and Gene Therapy advanced practice registered nurses,

 Allied health professionals in the fields of Cell and Gene Therapy,hematology, oncology, neurology, family medicine and internal medicine.

 Stem Cell Students, Scientists

 Stem Cell Researchers

 Stem Cell Faculty

 Stem Cell Associations and Societies

 Business Entrepreneurs

Session/Tracks

Cell Biology

Cell biology is a branch of biology that studies the different structures and functions of the cell and focuses mainly on the idea of the cell as the basic unit of life. Cell biology explains the structure, organization of the organelles they contain, their physiological properties, metabolic processes, signaling pathways, life cycle, and interactions with their environment. This is done both on a microscopic and molecular level as it encompasses prokaryotic cells and eukaryotic cells. Knowing the components of cells and how cells work is fundamental to all biological sciences; it is also essential for research in biomedical fields such as cancer, and other diseases. Research in cell biology is closely related to genetics, biochemistry, molecular biology, immunology, and developmental biology.

Chemical and molecular environment

Organelles

Growth and development

Gene therapy

Gene therapy and cell therapy are overlapping fields of biomedical research with the goals of repairing the direct cause of genetic diseases in the DNA or cellular population, respectively. The development of suitable gene therapy treatments for many genetic diseases and some acquired diseases has encountered many challenges and uncovered new insights into gene interactions and regulation. Further development often involves uncovering basic scientific knowledge of the affected tissues, cells, and genes, as well as redesigning vectors, formulations, and regulatory cassettes for the genes. Cell therapy is expanding its repertoire of cell types for administration. Cell therapy treatment strategies include isolation and transfer of specific stem cell populations, administration of effector cells, and induction of mature cells to become pluripotent cells, and reprogramming of mature cells.

Cell and gene therapy products

Articles containing or consisting of human cells or tissues that are intended for implantation, transplantation, infusion, or transfer to a human recipient. Gene therapies are novel and complex products that can offer unique challenges in product development. Hence, ongoing communication between the FDA and stakeholders is essential to meet these challenges. Gene therapy products are being developed around the world, the FDA is engaged in a number of international harmonization activities in this area.

Cancer gene therapy:

Cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecules ("molecular targets") that are involved in the growth, progression, and spread of cancer. Many cancer therapies have been approved by the Food and Drug Administration (FDA) to treat specific types of cancer. The development of targeted therapies requires the identification of good targets that is, targets that play a key role in cancer cell growth and survival. One approach to identifying potential targets is to compare the amounts of individual proteins in cancer cells with those in normal cells. Proteins that are present in cancer cells but not normal cells or that are more abundant in cancer cells would be potential targets, especially if they are known to be involved in cell growth or survival.

Viral gene therapy

Converting a virus into a vector the viral life cycle can be divided into two temporally distinct phases: infection and replication. For gene therapy to be successful, an appropriate amount of a therapeutic gene must be delivered to the target tissue without substantial toxicity. Each viral vector system is characterized by an inherent set of properties that affect its suitability for specific gene therapy applications. For some disorders, long-term expression from a relatively small proportion of cells would be sufficient (for example, genetic disorders), whereas other pathologies might require high, but transient, gene expression. For example, gene therapies designed to interfere with a viral infectious process or inhibit the growth of cancer cells by reconstitution of inactivated tumor suppressor genes may require gene transfer into a large fraction of the abnormal cells.

Stem cell therapies

Stem cells have tremendous promise to help us understand and treat a range of diseases, injuries, and other health-related conditions. Their potential is evident in the use of blood stem cells to treat diseases of the blood, a therapy that has saved the lives of thousands of children with leukaemia; and can be seen in the use of stem cells for tissue grafts to treat diseases or injury to the bone, skin and surface of the eye. Some bone, skin and corneal (eye) injuries and diseases can be treated by grafting or implanting tissues, and the healing process relies on stem cells within this implanted tissue.

Stem cell products

The global stem cell, Stem cell products market will grow from about $5.6 billion in 2013 to nearly $10.6 billion in 2018, registering a compound annual growth rate (CAGR) of 13.6% from 2013 through 2018.This track discusses the implications of stem cell research and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets.

Clinical trials in cell and gene therapy

A clinical trial is a research study that seeks to determine if a treatment is safe and effective. Advancing new cell and gene therapies (CGTs) from the laboratory into early-phase clinical trials has proven to be a complex task even for experienced investigators. Due to the wide variety of CGT products and their potential applications, a case-by-case assessment is warranted for the design of each clinical trial. Objectives: Determine the pharmacokinetics of this regimen by the persistence of modified T cells in the blood of these patients, Evaluate the immunogenicity of murine sequences in chimeric anti-CEA Ig TCR, Assess immunologic parameters which correlate with the efficacy of this regimen in these patients, Evaluate, in a preliminary manner, the efficacy of this regimen in patients with CEA bearing tumours.

Advanced gene therapy

Advanced therapies are different from conventional medicines, which are made from chemicals or proteins. Gene-therapy medicines: these contain genes that lead to a therapeutic effect. They work by inserting 'recombinant' genes into cells, usually to treat a variety of diseases, including genetic disorders, cancer or long-term diseases. Somatic-cell therapy medicines: these contain cells or tissues that have been manipulated to change their biological characteristics. Advanced Cell & Gene Therapy provides guidance in process development, GMP/GTP manufacturing, regulatory affairs, due diligence and strategy, specializing in cell therapy, gene therapy, and tissue-engineered regenerative medicine products.

Bioengineering therapeutics

The goals of bioengineering strategies for targeted cancer therapies are (1) to deliver a high dose of an anticancer drug directly to a cancer tumor, (2) to enhance drug uptake by malignant cells, and (3) to minimize drug uptake by non-malignant cells. In ESRD micro electro mechanical systems and nanotechnology to create components such as robust silicon Nanopore filters that mimic natural kidney structure for high-efficiency toxin clearance. It also uses tissue engineering to build a miniature bioreactor in which immune-isolated human-derived renal cells perform key functions, such as reabsorption of water and salts. In drug delivery for a leading cause of blindness, photo-etching fabrication techniques from the microchip industry to create thin-film and planar micro devices (dimensions in millionths of meters) with protective medication reservoirs and nanopores (measured in billionths of meters) for insertion in the back of the eye to deliver sustained doses of drug across protective retinal epithelial tissues over the course of several months.

Join The Discussion
Copyright © 2017-2018 Allied Academies, All Rights Reserved.